CHF 5993 100/6/12.5 µg
CCD-5993AA1-14
Phase 3 small_molecule completed
Quick answer
CHF 5993 100/6/12.5 µg for COPD (Chronic Obstructive Pulmonary Disease) is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A.
- Indication
- COPD (Chronic Obstructive Pulmonary Disease)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed